Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18606648 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | February 2025 | Allow | 11 | 0 | 0 | No | No |
| 18599838 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | November 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18599860 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | January 2025 | Allow | 10 | 0 | 0 | No | No |
| 18599888 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | January 2025 | Allow | 10 | 0 | 0 | No | No |
| 18599849 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | December 2024 | Allow | 9 | 0 | 0 | No | No |
| 18599924 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | March 2024 | January 2025 | Allow | 11 | 0 | 0 | No | No |
| 18585158 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | February 2024 | October 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18425844 | ANTI-VTCN1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | January 2024 | June 2025 | Allow | 16 | 2 | 0 | No | No |
| 18417063 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | January 2024 | December 2024 | Abandon | 11 | 1 | 0 | No | No |
| 18486445 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | October 2023 | April 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18475958 | Humanized Anti-GDNF family alpha-receptor 4 (GRF-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs) | September 2023 | December 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18324425 | T CELL RECEPTORS | May 2023 | February 2024 | Allow | 9 | 1 | 0 | No | No |
| 18180704 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF | March 2023 | May 2025 | Abandon | 26 | 2 | 0 | Yes | No |
| 18171208 | HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER | February 2023 | April 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18169240 | COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER | February 2023 | October 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18148903 | FORMULATIONS FOR PROMOTING HYDRATION AND METHODS OF USE THEREOF | December 2022 | March 2025 | Allow | 26 | 4 | 0 | Yes | No |
| 18147879 | PD1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS AN IMMUNOTHERAPY | December 2022 | October 2024 | Abandon | 21 | 1 | 0 | No | No |
| 18067672 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | December 2022 | July 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 18076997 | USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS | December 2022 | January 2024 | Allow | 14 | 2 | 0 | No | No |
| 18075648 | ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF FOR SPECIFICALLY RECOGNIZING B CELL MALIGNANCY, CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME AND USE THEREOF | December 2022 | June 2024 | Allow | 18 | 1 | 0 | No | No |
| 18055096 | D-DOMAIN CONTAINING POLYPEPTIDES AND USES THEREOF | November 2022 | September 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 18049736 | COMPOSITIONS AND METHODS FOR CANCER THERAPY | October 2022 | February 2024 | Allow | 16 | 2 | 1 | Yes | No |
| 18047327 | ANTI-HER2 NANOBODY AND CODING SEQUENCE AND USE THEREOF | October 2022 | May 2024 | Allow | 19 | 1 | 0 | Yes | No |
| 17816540 | CD123-Binding Polypeptides and Uses Thereof | August 2022 | October 2023 | Allow | 15 | 1 | 0 | No | No |
| 17767831 | Compositions and Methods for Targeting CD13 and TIM-3 with CAR T Cells to Treat Acute Myeloid Leukemia | April 2022 | April 2025 | Allow | 36 | 2 | 0 | No | No |
| 17673602 | Methods and Compositions for Determining Susceptibility to Treatment with Checkpoint Inhibitors | February 2022 | November 2024 | Abandon | 33 | 2 | 0 | No | No |
| 17576866 | PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | January 2022 | November 2023 | Allow | 22 | 0 | 1 | Yes | No |
| 17559329 | METHODS AND DELIVERY OF ALLOGENEIC CELL PRODUCTS | December 2021 | December 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17559500 | CANCER TREATMENT USING CD38 INHIBITOR AND/OR LENALIDOMIDE AND T-CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR | December 2021 | February 2024 | Abandon | 25 | 1 | 0 | No | No |
| 17552300 | T CELL RECEPTORS | December 2021 | April 2022 | Allow | 4 | 0 | 0 | No | No |
| 17537687 | CAR T-CELL ADJUVANT THERAPIES | November 2021 | July 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17522443 | CEACAM5 ANTIBODY-DRUG CONJUGATE FORMULATION | November 2021 | August 2024 | Allow | 33 | 3 | 0 | Yes | Yes |
| 17522623 | ANTIBODY DRUG CONJUGATES | November 2021 | March 2023 | Abandon | 16 | 0 | 0 | No | No |
| 17488685 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | September 2021 | March 2023 | Allow | 18 | 1 | 0 | No | No |
| 17488852 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | September 2021 | May 2023 | Allow | 20 | 1 | 0 | Yes | No |
| 17433692 | COMBINATION THERAPIES | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17433206 | CHIMERIC PROTEIN, METHOD OF PRODUCTION AND USE THEREOF, AND ALSO A NUCLEIC ACID MOLECULE, EXPRESSION CASSETTE, EXPRESSION VECTOR, HOST CELL, COMPOSITION FOR THE DIAGNOSIS OF LEISHMANIASIS, KIT FOR THE DIAGNOSIS OF LEISHMANIASIS AND METHOD OF DIAGNOSIS OF LEISHMANIASIS IN VITRO | August 2021 | February 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17433012 | USE OF NATRIURETIC PEPTIDES TO ASSESS AND TREAT ACUTE KIDNEY INJURY | August 2021 | April 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17427447 | NOVEL ANTI-PD-L1 ANTIBODY AND USES THEREOF | July 2021 | November 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17426548 | CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | July 2021 | June 2025 | Allow | 47 | 2 | 0 | No | No |
| 17311148 | IMMUNOSUPPRESIVE AGENT | June 2021 | October 2024 | Allow | 40 | 1 | 0 | Yes | No |
| 17338767 | COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS | June 2021 | January 2025 | Allow | 43 | 3 | 0 | Yes | No |
| 17298287 | TREATMENT OF ACUTE GVHD USING DONOR- SPECIFIC ANTI-HLA ANTIBODIES | May 2021 | April 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17331832 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | May 2021 | December 2024 | Abandon | 43 | 4 | 0 | No | No |
| 17291719 | Treatment for Giant Cell Arteritis | May 2021 | October 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17228871 | PSMA AND STEAP1 VACCINES AND THEIR USES | April 2021 | February 2025 | Abandon | 47 | 4 | 0 | Yes | No |
| 17177890 | METHODS AND AGENTS FOR TREATING ORGAN INJURY AND TRANSPLANT REJECTION | February 2021 | December 2023 | Abandon | 34 | 2 | 0 | Yes | No |
| 17166759 | METHOD OF TREATING CANCER BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS | February 2021 | October 2023 | Abandon | 32 | 4 | 0 | Yes | No |
| 17155251 | TRANSDERMAL SYSTEM FOR SYNERGISTIC IMMUNE-CHEMOTHERAPY USING MICRONEEDLES AND METHOD OF TREATMENT THEREOF | January 2021 | May 2025 | Abandon | 52 | 3 | 0 | Yes | No |
| 17144834 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY OF NPM1c-POSITIVE CANCER | January 2021 | September 2023 | Allow | 33 | 1 | 1 | Yes | No |
| 17092386 | VACCINATION WITH CANCER NEOANTIGENS | November 2020 | July 2024 | Abandon | 45 | 1 | 0 | No | No |
| 17089594 | USES OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTORS | November 2020 | January 2025 | Abandon | 51 | 4 | 0 | Yes | No |
| 17045406 | STABLE FORMULATIONS OF THERAPEUTIC ANTIBODY | October 2020 | June 2025 | Allow | 56 | 5 | 0 | Yes | No |
| 17037203 | Humanized Anti-GDNF family alpha-receptor 4 (GRF-alpha-4) Antibodies and Chimeric Antigen Receptors (CARs) | September 2020 | June 2023 | Allow | 33 | 2 | 0 | Yes | No |
| 17042838 | HUMANIZED ANTI-PROSTATE -SPECIFIC MEMBRANE ANTIGEN (PSMA) ANTIBODY DRUG CONJUGATES | September 2020 | May 2023 | Allow | 32 | 1 | 0 | Yes | No |
| 17041917 | TARGET FOR DRUG TREATMENT OF TUMOR METASTASIS AND USE THEREOF | September 2020 | April 2025 | Abandon | 55 | 3 | 0 | No | No |
| 17025991 | ANTIGEN BINDING MOLECULES FOR SMALL CELL LUNG CANCER | September 2020 | February 2025 | Allow | 53 | 4 | 0 | Yes | No |
| 17019059 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | September 2020 | June 2021 | Allow | 9 | 1 | 0 | No | No |
| 17019091 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | September 2020 | June 2021 | Allow | 9 | 1 | 0 | No | No |
| 16934745 | HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER | July 2020 | June 2023 | Abandon | 35 | 1 | 0 | No | No |
| 16932048 | COMBINATION THERAPY FOR TREATING OR PREVENTING CANCER | July 2020 | April 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16927661 | METHOD TO ISOLATE TCR GENES | July 2020 | May 2025 | Abandon | 58 | 3 | 1 | No | No |
| 16961133 | METHODS AND COMBINATION THERAPY TO TREAT CANCER | July 2020 | April 2023 | Abandon | 33 | 2 | 0 | No | No |
| 16961200 | EPIGENETIC MODIFIERS FOR USE IN CELLULAR IMMUNOTHERAPY | July 2020 | September 2023 | Abandon | 38 | 3 | 0 | Yes | No |
| 16957647 | NOVEL SCFV AMINO ACID SEQUENCE, CHIMERIC ANTIGEN RECEPTOR CONTAINING SAME AND APPLICATION THEREOF | June 2020 | December 2022 | Allow | 30 | 1 | 0 | No | No |
| 16771027 | NKG2D DARIC RECEPTORS | June 2020 | December 2023 | Abandon | 42 | 2 | 1 | No | No |
| 16768412 | Antibody Or Antigen Binding Fragment Thereof For Specifically Recognizing B Cell Malignancy, Chimeric Antigen Receptor Comprising Same And Use Thereof | May 2020 | November 2022 | Allow | 29 | 1 | 0 | No | No |
| 16767487 | COMPOSITIONS AND METHODS FOR TREATING CANCER | May 2020 | September 2023 | Abandon | 40 | 3 | 0 | Yes | No |
| 16766224 | ILDR2 ANTAGONISTS AND COMBINATIONS THEREOF | May 2020 | January 2023 | Allow | 32 | 2 | 0 | No | No |
| 16766128 | POLYPEPTIDE | May 2020 | January 2023 | Allow | 31 | 1 | 0 | No | No |
| 16877907 | USE OF IGF-1 IN THE PREPARATION OF MEDICAMENTS FOR PREVENTING AND/OR TREATING LIVER TUMORS | May 2020 | June 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16764248 | Methods of Treating Glioblastoma | May 2020 | October 2023 | Abandon | 41 | 2 | 0 | Yes | No |
| 15931789 | MEDICAMENT FOR CANCER TREATMENT | May 2020 | June 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 16763539 | CELL | May 2020 | January 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16868927 | Antibodies Reactive with B7-H3, Immunologically Active Fragments Thereof and Uses Thereof | May 2020 | October 2024 | Abandon | 53 | 3 | 0 | No | No |
| 16761784 | Inhibition of CTLA-4 and/or PD-1 For Regulation of T Cells | May 2020 | October 2024 | Abandon | 53 | 6 | 0 | No | No |
| 16864478 | CD123-Binding Polypeptides and Uses Thereof | May 2020 | May 2022 | Allow | 24 | 1 | 0 | No | No |
| 16760179 | ANTI-CD5L ANTIBODY AND USES THEREOF | April 2020 | March 2022 | Allow | 23 | 1 | 0 | No | No |
| 16760382 | METHODS ASSOCIATED WITH TUMOR BURDEN FOR ASSESSING RESPONSE TO A CELL THERAPY | April 2020 | September 2022 | Allow | 29 | 2 | 0 | No | No |
| 16858509 | AMATOXIN ANTIBODY-DRUG CONJUGATES AND USES THEREOF | April 2020 | October 2023 | Abandon | 41 | 2 | 1 | No | No |
| 16758474 | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | April 2020 | February 2023 | Allow | 34 | 1 | 0 | No | No |
| 16758124 | ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD123 AND USES THEREOF | April 2020 | November 2022 | Allow | 31 | 1 | 0 | No | No |
| 16757156 | ANTI-VISTA ANTIBODY AND USE THEREOF | April 2020 | March 2022 | Allow | 23 | 1 | 1 | No | No |
| 16851725 | REPROGRAMMING OF POLYMORPHONUCLEAR LEUKOCYTES | April 2020 | February 2023 | Abandon | 34 | 1 | 0 | No | No |
| 16652230 | METHOD FOR TREATING GLIOBLASTOMA | March 2020 | June 2023 | Abandon | 39 | 2 | 0 | Yes | No |
| 16652011 | PRODUCTION METHOD FOR IPS CELL-DERIVED POPULATION OF GENETICALLY DIVERSE T CELLS | March 2020 | October 2024 | Abandon | 54 | 5 | 0 | No | No |
| 16832440 | DOSING OF A BISPECIFIC ANTIBODY THAT BINDS PD1 AND CTLA4 | March 2020 | June 2024 | Abandon | 51 | 6 | 0 | No | No |
| 16832170 | SEMAPHORIN-4D ANTAGONISTS FOR USE IN CANCER THERAPY | March 2020 | January 2025 | Abandon | 58 | 6 | 1 | No | No |
| 16650884 | PD1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR AS AN IMMUNOTHERAPY | March 2020 | May 2022 | Allow | 26 | 1 | 0 | No | No |
| 16649914 | METHOD FOR TREATING MYELOID LEUKEMIA | March 2020 | July 2023 | Abandon | 40 | 2 | 0 | No | No |
| 16649763 | ANTI IGF, ANTI PD-1, ANTI-CANCER COMBINATION THERAPY | March 2020 | June 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16826405 | COMPOUNDS AND CONJUGATES THEREOF | March 2020 | February 2024 | Abandon | 47 | 2 | 1 | Yes | No |
| 16649157 | NOVEL ANTI-CD19 ANTIBODIES | March 2020 | July 2022 | Allow | 28 | 1 | 0 | No | No |
| 16823987 | CD28 T CELL CULTURES, COMPOSITIONS, AND METHODS OF USING THEREOF | March 2020 | February 2025 | Abandon | 59 | 2 | 1 | No | No |
| 16648033 | ANTI-PD-L1 ANTIBODY AND USES THEREOF | March 2020 | July 2022 | Allow | 28 | 1 | 1 | No | No |
| 16645247 | GENETICALLY ENGINEERED T CELL AND APPLICATION THEREOF | March 2020 | June 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16645064 | IMMUNOCONJUGATES COMPRISING SIGNAL REGULATORY PROTEIN ALPHA | March 2020 | August 2022 | Allow | 29 | 1 | 1 | No | No |
| 16791217 | Combination Therapy For Treatment Of B-Cell Malignancies | February 2020 | October 2024 | Abandon | 56 | 5 | 1 | No | No |
| 16637972 | Reprogramming of CD8 T Cells with CXCL12 Signaling Inhibitors | February 2020 | November 2022 | Abandon | 33 | 2 | 0 | No | No |
| 16637600 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER OR COLORECTAL CANCER WITH LIVER METASTASES WITH AN ANTI PD-L1 ANTIBODY AND AN ONCOLYTIC VIRUS | February 2020 | June 2022 | Abandon | 28 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BUTTICE, AUDREY L.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BUTTICE, AUDREY L works in Art Unit 1647 and has examined 107 patent applications in our dataset. With an allowance rate of 44.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner BUTTICE, AUDREY L's allowance rate of 44.9% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BUTTICE, AUDREY L receive 2.07 office actions before reaching final disposition. This places the examiner in the 69% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by BUTTICE, AUDREY L is 34 months. This places the examiner in the 22% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +18.2% benefit to allowance rate for applications examined by BUTTICE, AUDREY L. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 17.7% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 15.4% of cases where such amendments are filed. This entry rate is in the 10% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.